What have imaging studies with evolocumab yielded?

Abstract

This review describes usual endpoints in trials assessing changes of atherosclerotic plaques during lipid-lowering therapy. Authors focus their attention to the trials using evolocumab as an active drug.

Keywords

• optical coherence tomography
• evolocumab
• atherosclerosis regression
• intravascular ultrasound